Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GENETICS INSTITUTE/CHUGAI's "BEST MODE" DEFENSE AGAINST AMGEN

Executive Summary

GENETICS INSTITUTE/CHUGAI's "BEST MODE" DEFENSE AGAINST AMGEN in the erythropoietin patent dispute between the companies was discussed by New York patent attorney Jennifer Gordon (Pennie & Edmonds) at a Nov. 6 Shearson Lehman Hutton health care conference in New York. With the "best mode" of production argument, Gordon elaborated, "Genetics Institute apparently thinks it has evidence that the inventors [of the Amgen product] had particular clones or particular vectors that they preferred for making EPO by recombinant means, and apparently, these preferred materials were not deposited [in support of the patent] as of a certain critical date." The best mode defense was among the issues raised by Genetics Institute and Chugai in oral arguments given Nov. 9 in Boston federal court (see preceding T&G). * Failure to provide the best mode for carrying out an invention, Gordon pointed out, was one of the arguments cited in Scripps Clinic v. Genentech. Decided in March, that suit involves patents for recombinant Factor VIII:C products. Gordon noted that one of the reasons the Scripps patent was found to be invalid was that the company failed to disclose a preferred monoclonal antibody for purification procedures which the inventors knew about. Scripps is appealing the decision. The U.S. Patent and Trademark Office, Gordon added, is proposing to amend the duty of disclosure standard for submission of patent information through proposed rule 57, published in the Federal Register last March. The proposed rule contains language that would make it easier for a patent applicant to determine what information is crucial to disclose.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS045148

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel